04/06/2026 Amneal secures FDA nod and 180‑day CGT exclusivity for ready‑to‑use romidepsin injection in cutaneous T‑cell lymphoma Amneal secures FDA nod and 180‑day CGT exclusivity for ready‑to‑use romidepsin injection in cutaneous T‑cell lymphoma (Ref) Amneal received US FDA approval for its romidepsin injection solution (27.5 mg/5.5 mL), supplied in ready-to-use vials Competitive Generic Therapy (CGT): The product qualifies for CGT designation, granting 180 days of market ex

April 3rd Week, 2025 Regulatory Events 🎯 Bristol Myers Squibb ’s nivolumab (anti-PD-1) + ipilimumab (anti-CTLA-4) has been approved...